Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2025 07:00 ET | Source: Charm Therapeutics

CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)

PRESS RELEASE AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutationsFirst-in-human...
September 08, 2025 02:00 ET | Source: Charm Therapeutics

CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer

PRESS RELEASE CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer LONDON – 8 September 2025 -- CHARM Therapeutics (“CHARM”, “The Company”), announces the appointment of Dr Erkut...
September 02, 2025 07:00 ET | Source: Charm Therapeutics

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
September 02, 2025 02:00 ET | Source: Charm Therapeutics

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
July 24, 2025 07:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Appoints Julianne Averill to its Board of Directors

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today...
December 12, 2024 17:02 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels...
December 08, 2023 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
June 14, 2023 07:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
June 13, 2023 16:01 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
June 11, 2023 03:45 ET | Source: Kura Oncology, Inc.

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH...